Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Transmission and prevention news

Show

From To
Should everyone be getting the HIV prevention pill as part of this HIV vaccine study?

More than 500 people have signed up since December to be part of the country’s largest HIV vaccine trial, but some experts are crying foul over what they say is unequal access to the HIV prevention pill among participants.

Published
30 June 2017
From
Bhekisisa
I’m HIV-positive. But thanks to drugs, no one can catch the virus from me

Advances in medication now mean that the virus can no longer be detected in my blood, so it’s impossible for me to transmit it to anybody.

Published
29 June 2017
From
The Guardian
‘We must listen to science, not stigma. People on effective HIV treatment cannot pass on the virus.’

Medical evidence has shown that people living with HIV and who are on effective treatment cannot pass on the virus. However, a major new survey by Terrence Higgins Trust has shown that only 9% of the British public are aware of this fact, which has been evidenced by scientific research.

Published
29 June 2017
From
Terrence Higgins Trust
Support Groups a Driver to PrEP Rollout in Kenya

Kenya passed a major milestone in the fight against HIV on May 4, 2017 when it launched a nation-wide initiative to bring oral PrEP (pre-exposure prophylaxis), antiretroviral drugs for preventing HIV, to the people who need it. A team made up of LVCT Health staff and AVAC staff recently visited the implementing sites to gather stories and collect lessons learnt as part of the OPTIONS project. We interviewed providers, adherence counselors and people using PrEP who shared their journeys of PrEP uptake and adherence.

Published
28 June 2017
From
AVAC
“A Quarter for Prevention”: Study finds Global Fund investments in HIV prevention in Africa fall short

Across 15 countries, just 15% of grant programs from the 2014-2016 funding cycle went towards HIV prevention.

Published
28 June 2017
From
Global Fund Observer
Why Did the Opioid Epidemic Develop and How Do We Stop It?

In the 1980s, evidence from acute pain and end-of-life palliative care was applied to prescribing opiates for chronic long-term pain. Purdue Pharma, the manufacturer of oxycodone (OxyCotin), spent $10 million to advertise the drug during its first year of sales, increasing that amount to $28 million by the fifth year after the drug was approved in the U.S.

Published
28 June 2017
From
The Body PRO
Washington DC reports sharp decline in new HIV infections

In 2007, D.C. residents were diagnosed with HIV at a rate of nearly four per day. That rate dropped to less than one resident per day in 2016. The 73 percent decline in new cases — from 1,333 in 2007 to 347 in 2016 — can be attributed to factors that include a needle-exchange program, condom distribution and increasing use of preventive medication to halt the spread of the disease, city officials said Tuesday.

Published
28 June 2017
From
Washington Post
Why opioid deaths are this generation’s Aids crisis

The soaring numbers of deaths from overdoses in the US and UK require a radical and fast rethink of drugs policy.

Published
27 June 2017
From
The Guardian
Charlie Sheen sued again for allegedly exposing ex to HIV

Charlie Sheen is being sued again by an ex who claims the “Two and a Half Men” star lied about his HIV.

Published
26 June 2017
From
New York Daily News
Fall in new HIV diagnoses among men who have sex with men (MSM) at selected London sexual health clinics since early 2015: testing or treatment or pre-exposure prophylaxis (PrEP)?

Since October 2015 up to September 2016, HIV diagnoses fell by 32% compared with October 2014–September 2015 among men who have sex with men (MSM) attending selected London sexual health clinics. This coincided with high HIV testing volumes and rapid initiation of treatment on diagnosis. The fall was most apparent in new HIV testers. Intensified testing of high-risk populations, combined with immediately received anti-retroviral therapy and a pre-exposure prophylaxis (PrEP) programme, may make elimination of HIV achievable.

Published
26 June 2017
From
Eurosurveillance

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.